Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

A new approach for the synthesis of pharmaceutically relevant fluorinated phenanthridines

Phenanthridines are heterocyclic compounds consisting of two six-membered benzene rings fused to a six-membered ring containing nitrogen.

26 Jun 2023

Stanford and Intonation partner to develop new treatments for neuroendocrine tumors

Stanford University's Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) have formed a collaboration to develop treatments that target cancerous neuroendocrine tumors, or tumors that form from hormone-releasing cells.

23 Jun 2023

Plant based compound peruvoside may be able to prevent up to 12 medically important viruses

Peruvoside, a plant-based compound that is commonly used to treat heart failure, has been discovered to be able to prevent up to 12 medically important viruses, all originating from different virus families.

22 Jun 2023

Repurposing cancer drugs for malaria treatment

With malaria becoming increasingly drug-resistant, a team of UCF researchers is looking to use cancer drugs to accelerate the discovery of new life-saving therapies for the disease.

21 Jun 2023

Novel approach to multimodal aging clock for interpretable age prediction and target discovery

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 11, entitled, "Precious1GPT: multimodal transformer-based transfer learning for aging clock development and feature importance analysis for aging and age-related disease target discovery."

21 Jun 2023

UTHSC researchers receive major national award to find new treatments for breast cancer metastasis

UTHSC researchers working to find new treatments to combat breast cancer metastasis recently pulled in a major national award.

20 Jun 2023

INTEGRA Biosciences’ pipettes help to advance cancer drug discovery

The Institute for Cancer Research (ICR), part of the University of London, is using VIAFLO electronic pipettes from INTEGRA Biosciences to streamline its preclinical drug screening and translational medicine workflows.

From INTEGRA Biosciences 20 Jun 2023

ACROBiosystems Aneuro Partners with Diagnostic Biochips to Accelerate Neuroscience Drug Discovery

ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips.

From ACROBiosystems 19 Jun 2023

COVID-19 susceptibility mechanism discovered using a newly created tool

Researchers have discovered a mechanism for COVID-19 susceptibility using a newly created tool. The tool, GASPACHO, captures dynamic changes in gene expression along the innate immune response, allowing researchers to identify genes and molecular pathways associated with disease risk that have previously been too complex to detect or interpret.

15 Jun 2023

Insilico announces new multimodal transformer-based aging clock for processing diverse data sets

Clinical stage generative artificial intelligence (AI)-driven drug discovery company Insilico Medicine ("Insilico") has announced a new multimodal transformer-based aging clock that is capable of processing diverse data sets and providing insights into biomarkers for aging, mapping them to genes relevant to both aging and disease, and discovering new therapeutic targets designed to slow or reverse both aging and aging-related diseases.

15 Jun 2023

Breast cancer drug development work moves forward with support from STTR grant

Triple negative breast cancer is an aggressive subtype of breast cancer with worse survival outcomes than most.

14 Jun 2023

Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US operations

Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr. Steve Jenkinson as Vice President, Drug Discovery and Safety Assessment. The US-based appointment represents an important step in the expansion of Metrion’s business, driven by its ion channel discovery capabilities.

From Metrion Biosciences Limited 12 Jun 2023

Keynote speakers of ELRIG Drug Discovery 2023 announced

The European Laboratory Research & Innovation Group (ELRIG) UK today announced the keynote speakers for Drug Discovery 2023, taking place at the ACC in Liverpool from 18–19 October. Prof Janet Hemingway CBE, FRS, Founding Director of Infection Innovation Consortium (iiCON), and Dr Dave Powell, Chief Scientific Officer (CSO) of LifeArc will lead this year’s event focussing on diverse thinking and new perspectives.

10 Jun 2023

New model can quickly screen large libraries of potential drug compounds

Huge libraries of drug compounds may hold potential treatments for a variety of diseases, such as cancer or heart disease.

9 Jun 2023

Insilico Medicine nominates pan-TEAD inhibitor as a potential solution for drug resistance in solid tumor patients

Insilico Medicine, a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM6331, a potential best-in-class pan-TEAD inhibitor, as a preclinical candidate compound (PCC) generated by Chemistry42, its proprietary generative chemistry-driven molecule design engine, targeting the Hippo pathway for the treatment of advanced solid tumors.

8 Jun 2023

Axol Bioscience collaborates with StrataStem to deliver stem cell based ‘clinical trial in a dish’ for Alzheimer’s disease

Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples.

From Axol Bioscience Ltd 7 Jun 2023

Global partnership to make UQ a major international hub for vaccine discovery and development

Queensland will become a major international hub for vaccine discovery and development with a global partnership formed in the United States today to help address the world's critical health challenges.

6 Jun 2023

ELRIG UK Announces Prof Janet Hemingway and Dr Dave Powell as Keynote Speakers at Drug Discovery 2023

ELRIG Drug Discovery 2023 at ACC Liverpool (18–19 October) to focus on diverse thinking and new perspectives.

From ELRIG (UK) Ltd. 6 Jun 2023

Study provides a treasure trove of information on molecular biology of the immune system

Researchers at Sanford Burnham Prebys, collaborating with scientists from Eli Lilly and Company, have revealed the structure and function of a drug called LY3361237, which can reduce the harmful activity of the immune system to help treat autoimmune diseases.

5 Jun 2023

Innovative probe could deepen the understanding of key cellular messenger and lead to new drug discoveries

A ground-breaking study by Loughborough University and the University of Oxford has led to the development of a small molecule probe that could deepen our understanding of a crucial cellular messenger and lead to the development of new therapeutic drugs.